1 1 Abbreviations: aSyn, alpha-synuclein; cell lines stably overexpressing human A53T mutated form of aSyn, [A53T]aSyn or A30P mutated form of aSyn, [A30P]aSyn; high-molecularweight, HMW; microtubule-associated protein light chain 3B I-II, LC3BI-II; negative control, NC; optical density, OD; Parkinson's disease, PD; prolyl oligopeptidase, PREP; ubiquitinproteasome system, UPS; Western blot, WB; Wild type, Wt.
Introduction
In Parkinson's disease (PD), degeneration of dopaminergic neurons in substantia nigra and striatum leads to progressing movement deficits. The cause for this neurodegeneration is not known but histopathological findings of PD are insoluble inclusions, Lewy bodies, mainly consisting of an α-synuclein (aSyn) [1] .
aSyn is a natively unfolded protein that can misfold, leading to protein aggregation, formation of toxic oligomers and cell-to-cell propagation of aSyn pathology [2] [3] [4] . Moreover, genomewide association studies have pointed aSyn gene, SNCA, as a risk factor for PD and mutations in SNCA are associated with familial forms of PD, supporting its participation in PD pathology (for review, see [5] ). The most studied point mutations in SNCA are A30P and A53T, causing familial PD with early onset. Both of them enhance the fibrillization of aSyn, leading to aSyn oligomers and cellular damages, but A30P is more prone for membrane-induced aggregation (for review, see, [6] ). In addition to damaging several cellular organelles, aSyn overexpression and aSyn oligomers have been shown to inhibit ubiquitin-proteasome system (UPS) [7, 8] , and decreased proteasomal activity in the substantia nigra has been identified in PD patients [9] .
Moreover, aSyn can inhibit and impair chaperone-mediated autophagy [10] and macroautophagy (referred as autophagy hereafter) [11] , thus inducing its own accumulation. In addition, several reports show that proteasomal inhibition induces the aggregation of aSyn in cells and in vivo [12] [13] [14] , stressing the importance of proteolytic balance in protein aggregation diseases.
Several factors can induce and enhance the aggregation process of aSyn (for review, see [4] ).
On of them is prolyl oligopeptidase (PREP), a serine protease that can increase the aggregation of aSyn via direct protein-protein interaction [15, 16] . PREP is also colocalized with aSyn in substantia nigra of post mortem samples of PD patients, supporting the role of this interaction in PD pathology [17] . Recently, we have shown that inhibition of PREP by a small-molecule inhibitor reduces aSyn protein aggregation in vitro and in vivo by modifying the interaction between PREP and aSyn [15, [18] [19] [20] . Moreover, we have shown that PREP is a negative regulator of autophagy and that PREP inhibition enhances the autophagic flux via beclin1 dependent manner [19] , leading to decreased amount of high-molecular weight (HMW) aSyn oligomers in cells and in aSyn transgenic mouse models.
Several studies suggest that when proteasomal processing of the proteins is impaired, autophagy becomes important in degradation of accumulated proteins (for review, see [21] ). Moreover, induction of autophagy is shown attenuate the toxicity of aSyn aggregation (for review, see [21] ). Thus, based on our previous findings, we wanted to test whether inhibition of PREP is protective against a proteasomal inhibitor, lactacystin, induced toxicity and protein accumulation in aSyn overexpressing cell culture.
Materials and methods

Chemicals
Chemicals used were purchased form Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Ethanol was purchased from Altia (Helsinki, Finland). Lactacystin was purchased from A.G. Scientific (#L-1147; San Diego, CA, USA) and dissolved in PBS in concentration of 2mg/ml. The PREP inhibitor, KYP-2047 (4-phenylbutanoyl-l-prolyl-2(S)cyanopyrrolidine), was synthesized in School of Pharmacy, University of Eastern Finland, as previously described [22] . KYP-2047 has been shown to be highly potent, brain and cell penetrating and specific for PREP [23, 24] . KYP-2047 was dissolved in DMSO at a concentration of 100 mM for stock.
Cell lines
Stable cell lines overexpressing human A53T ([A53T]aSyn) or A30P aSyn ([A30P]aSyn) were generated using a lentiviral vector as described in [25] . SH-SY5Y human neuroblastoma cell line without aSyn overexpression (Wt cells) was purchased from ATCC (LGC Standards; #CRL-2266, Middlesex, UK). Cells were cultured with Dulbecco's modified eagle medium (DMEM-Glutamax, #31966-021; ThermoFisher, Waltham, MA, USA) containing 15% fetal bovine serum (FBS, #16000-044; ThermoFisher), 1% non-essential amino acids (NEAA, #11140; ThermoFisher) and 50 µg/ml Gentamycin (#15750-094; ThermoFisher). With aSyn overexpressing cells 1 µg/ml puromycin was added to medium for selection [18] .
Induction of aSyn aggregation by lactacystin, a proteasomal inhibitor
For Western blot (WB) and proteasomal activity experiments, the cells were seeded in a 6-well plate with the density 400,000 cells/well and allowed to attach overnight. Thereafter, the cells were incubated for 24 h on 10 µM lactacystin with 1 µM KYP-2047 or 0.001% DMSO (vehicle control). The concentration of KYP-2047 was chosen based on earlier studies [18, 19] and on dose-response experiment ( Fig. S1A in supplementary material). Lactacystin dose was chosen based on cell viability results on dose-response experiments ( Fig. 1B-D) . After the incubation, the cells were homogenized as described below.
Proteasome activity assay
For determining chymotrypsin-like 20S proteasomal activity, the protocol based on Suc-Leu-Leu-Val-Tyr-AMC (#I-1395, Bachem, Bubendorf, Switzerland) substrate was used as described in [19] . The fluorescence was read with Victor 2 well-plate reader (PerkinElmer, Waltham, MA, USA) and all assays were done in triplicate.
Cell viability assay
Cells were plated with the density of 50,000 cell/well in 96-well plate and the next day incubated for 24 h with variable concentrations of lactacystin (10 nM, 100 nM, 1 µM, 10 µM and 100 µM) in the presence of 1 µM KYP-2047 or DMSO vehicle (0.001% DMSO; 150 µL/well). To assess cell viability a standard LDH release assay was performed as previously described [18] .
Cell fractionation and WB
WB was used to detect aSyn, ubiquitin accumulation and autophagy markers from cellular fractions. The cells were fractioned to TBS soluble (soluble aSyn), Triton X-100 soluble (membrane-bound aSyn) and SDS soluble (containing SDS soluble and insoluble aSyn conformations) fractions as described in [26] . Before WB, the protein concentrations of TBS and Triton X-100 fractions were measured by using BCA method (Bio-Rad, Hercules, CA, USA), and the samples were loaded to 4-20% TGX gels (Bio-Rad) with equal protein amounts.
The loading of SDS-fraction was based on protein amount of triton X-100 soluble fraction.
Standard SDS-PAGE techniques were used, and the membranes were incubated +4 ºC overnight in 5% skim milk in 0.05% Tween20 in TBS. Following primary antibodies were used: 
Results
The effect of lactacystin and KYP-2047 on cell viability
The effect of PREP inhibition on lactacystin-induced aSyn aggregation
Lactacystin incubation increased the levels of aSyn dimers (37 kDA band) but did not have an effect on the levels of higher molecular weight aSyn forms in TBS fraction of either cell line ( Fig. 2A) 
The effect of lactacystin and PREP inhibition on proteasomal and autophagy markers
Ubiquitin levels were significantly increased after lactacystin administration in TBS soluble fraction of Wt (increase of 60-72%) and [A53T]aSyn cells (increase of 73%) ( Fig. 2D ; Wt, P=0.0140; F2,8 = 9.436; [A53T]aSyn, P=0.0082; F2,8=11.87; 1-way ANOVA), and KYP-2047 had no effect on ubiquitin levels. No significant increase was seen in Triton-X or SDS fractions ( Fig. 2E-F) .
The levels of a protein accumulation marker, p62, was increased in TBS and SDS fractions Furthermore, lactacystin had no effect on beclin1 protein levels ( Fig. 3E ) but KYP-2047 had a trend to increase beclin1 protein levels (no significance in OD analysis) as seen in our previous study [19] . We also studied the effect of LC and KYP-2047 on parkin, an ubiquitin E3 ligase, which participates in protein ubiquitination and UPS targeting. We observed significantly decreased levels of parkin after LC treatment and KYP-2047 had no effect on parkin levels . LC incubation caused an increase on the autophagosome marker, LC3BII (D) but it was not statistically significant in optical density (OD) analysis. In wild-type (Wt) and [A53T]aSyn cells, KYP-2047 had significant effect on LC3BII compared to vehicle treatment. LC did not alter beclin1 levels (E) while KYP-2047 had a trend to increase beclin1 amounts. Parkin1 levels were significantly decreased by LC (F) and KYP-2047 did not have effect on this. * P < 0.05, ** P < 0.01, *** P < 0.001, Newman-Keuls post-hoc test, 1-way ANOVA.
Discussion
In this study, we have shown that a PREP inhibitor, KYP-2047, effectively attenuates the toxic effects of lactacystin in mutated aSyn overexpressing cells by decreasing the levels of accumulated mutated aSyn.
After aSyn and its aggregation has been identified as one of the key players in PD pathophysiology, also proteolytic balance has raised interest in PD research since decreased proteasomal activities [9] and reduced lysosomal markers (for review, see [27] ) have been found from PD patients. UPS and chaperone-mediated autophagy are mainly responsible for degradation of soluble aSyn. However, misfolding and aggregation of aSyn leads to protein accumulation, deficits on UPS and chaperone-mediated autophagy, and thereafter to induction of autophagy, which can also degrade oligomeric forms of aSyn (for reviews, see [28] ).
Several studies show that activating autophagy may be beneficial to neuronal survival in aSyn aggregation models (for review, see [21] ). We showed in our previous study that a PREP inhibitor, KYP-2047, enhanced autophagy via beclin1 dependent mechanism and decreased the amount of HMW aSyn in cell culture and in the brain of aSyn transgenic mouse [19, 20] . Therefore, we wanted to test if PREP inhibition can overcome the aSyn aggregation induced by proteasomal deficit in a cellular model. Our results show that the inhibition of proteasomal activity in mutated aSyn overexpressing cells resulted in a dose-dependent reduction of cell viability and increase in aSyn oligomerization whereas cells without mutated aSyn overexpression were more resistant to lactacystin-induced cell death, supporting the significance of aSyn aggregation in lactacystin induced toxicity. Treatment of aSyn overexpressing cell lines with KYP-2047 significantly improved cell survival together with reduced HMW aSyn oligomers and SDS-insoluble p62, suggesting induced autophagy.
Interestingly, [A30P]aSyn overexpressing cells showed accumulation also in TrX fraction and KYP-2047 did not have any effect on this. When considering that A30P[aSyn] is more prone for membrane-associated aggregation than other forms of aSyn [6] , this suggests that PREP inhibitors are effective towards aggregation occurring in cytosol. Although we did not see significant increase in LC3BII and Beclin1 in this study, these markers showed increasing trend, and taken together with the decrease in SDS-soluble p62, a protein accumulation marker, the effects of KYP-2047 seem specific for insoluble aggregated proteins, emphasizing the role for autophagy. Our current and previous results suggest that PREP regulates PI3K class 3 mediated autophagy pathway, and the exact role of PREP on this pathway needs to be studied further.
We saw increased ubiquitin protein levels only in soluble fraction of [A53T]aSyn overexpressing cells. Increased ubiquitin load indicates declined proteasomal activity, and is also associated to Lewy bodies of PD. However, lactacystin does not seem to induce accumulation of insoluble ubiquitin positive proteins. This might be explained by our observation of reduced parkin protein amount after lactacystin treatment. Parkin is important for ubiquitinylation of proteins which has been shown to be downregulated after lactacystin also in previous study [29] . KYP-2047 did not alter the ubiquitin levels but reduced p62 and aSyn oligomers in SDS-fraction suggest that PREP inhibition does not affect directly on degradation of soluble proteins but is more effective in inducing autophagy and clearance of insoluble proteins and aggregates.
Conclusions
Our results show that aSyn overexpression promotes lactacystin-induced toxicity and KYP-2047 protects cells against cell death by decreasing insoluble mutated aSyn oligomers and p62 levels. Several diseases with protein accumulation, including neurodegenerative diseases, would benefit from autophagy enhancement but there have been various problems, such as specificity and toxicity, in developing autophagy enhancers for clinical use [30] . However, PREP inhibition may offer novel means to induce autophagy and treat synucleinopathies as well as other protein aggregating diseases Supplementary material for manuscript "Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture" Figure S1A 
